Intratumoral PH-762 for Cutaneous Carcinoma

StatusCompleted
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 5 more changesShow less
    • Final enrollment: 22 participants (planned 30)
    • Study completion date changed from estimate of Mar 2026 to Mar 17, 2026
    • Eligibility criteria expanded, about 11 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Publications: details revised at 1 of 1 entry
  2. Primary completion date changed from estimate of Jan 2026 to Dec 29, 2025
    • Study completion date: Apr 2026 to Mar 2026
    v13
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 5 of 5 sites
    v12
  4. Primary completion date: Jun 2025 to Jan 2026
    • Study completion date: Sep 2025 to Apr 2026
    • Study sites revised (5)
    v11
  5. Study sites revised (5)v10
Show 8 earlier versionsHide 8 earlier versions
  1. Site details revised at 1 of 5 sitesv9
  2. Study sites: 4 to 5v8
  3. Collaborators expanded, about 2 wordsv7
  4. Re-verified, no change to tracked fieldsv6
  5. Site details revised at 1 of 4 sitesv5
  6. Re-verified, no change to tracked fieldsv4
  7. Study sites: 2 to 4v3
  8. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 1 to 2
    • Start date changed from estimate of Sep 2023 to Nov 7, 2023
    • Secondary endpoints revised (5)
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to evaluate the safety and tolerability of intratumoral injections of PH-762 in squamous cell carcinoma, melanoma, or Merkel cell carcinomas of the skin, to understand what the body does to the PH-762, and to observe how the tumor responds to the drug. Participants will receive four injections of PH-762 at weekly intervals, into a single tumor, followed by surgical removal of the tumor approximately two weeks later.
Trial Details
NCT Number NCT06014086
Lead Sponsor Phio Pharmaceuticals Inc.
Collaborators: Prosoft Clinical
Conditions
(from sponsor)		 Squamous Cell Carcinoma of the Skin, Malignant Melanoma of Skin, Merkel Cell Carcinoma of Skin
Related terms Melanoma
Enrollment 22 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov